A limitation of the current study that needs to be considered is the small number of C9orf72 mutation carriers enrolled (N = 13) which rendered subdividing C9orf72 mutation carriers in FTD, FTD/ALS and ALS patients impossible. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.